NEW YORK, May 28, 2013 /PRNewswire/ -- Harwood Feffer
LLP (www.hfesq.com) is investigating potential claims against the
board of directors of Omthera Pharmaceuticals, Inc. ("Omthera" or
the "Company") (NASDAQ: OMTH) concerning the proposed acquisition
of the Company by AstraZeneca Plc
("AstraZeneca").
(Logo: http://photos.prnewswire.com/prnh/20120215/MM54604LOGO
)
On May 28, 2013, Omthera announced
that it had entered into a definitive agreement pursuant to which
the Company will be acquired by AstraZeneca. Under the terms
of the agreement, Omthera stockholders will receive $12.70 in cash for each share of Omthera
owned.
Our investigation concerns whether the Omthera board of
directors is fulfilling its fiduciary duties, maximizing the value
of the Company, disclosing all material benefits and costs, and
obtaining full and fair consideration for Company
shareholders.
If you own Omthera shares and wish to discuss this matter with
us, or have any questions concerning your rights and interests with
regard to this matter, please contact:
Benjamin Sachs-Michaels, Esq.
Robert I. Harwood, Esq.
Craig Lowther
Harwood Feffer LLP
488 Madison Avenue
New York, New York 10022
Phone Numbers: (877) 935-7400
(212)935-7400
Email: bsachsmichaels@hfesq.com
Website: http://www.hfesq.com
Harwood Feffer has been
representing individual and institutional investors for many years,
serving as lead counsel in numerous cases in federal and state
courts. Please visit the Harwood Feffer LLP website
(http://www.hfesq.com) for more information about the firm.
Attorney Advertising © 2013 Harwood Feffer LLP. The law firm
responsible for this advertisement is Harwood Feffer LLP
(www.hfesq.com). Prior results do not guarantee or predict a
similar outcome with respect to any future matter.
SOURCE Harwood Feffer LLP